Meridian Bioscience Inc. (NASDAQ:VIVO) Chairman John A. Kraeutler acquired 5,000 shares of the business’s stock in a transaction on Friday, November 4th. The shares were bought at an average cost of $16.13 per share, with a total value of $80,650.00. Following the completion of the acquisition, the chairman now owns 316,683 shares in the company, valued at $5,108,096.79. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Meridian Bioscience Inc. (NASDAQ:VIVO) opened at 16.95 on Thursday. The stock has a market capitalization of $713.36 million, a price-to-earnings ratio of 20.18 and a beta of 0.94. Meridian Bioscience Inc. has a 12-month low of $15.75 and a 12-month high of $21.49. The company has a 50 day moving average of $18.03 and a 200-day moving average of $19.07.

Several large investors have recently added to or reduced their stakes in VIVO. Renaissance Technologies LLC increased its stake in Meridian Bioscience by 8.6% in the first quarter. Renaissance Technologies LLC now owns 1,710,600 shares of the company’s stock worth $35,255,000 after buying an additional 136,024 shares during the period. Prudential Financial Inc. increased its stake in Meridian Bioscience by 3.9% in the first quarter. Prudential Financial Inc. now owns 100,591 shares of the company’s stock worth $2,073,000 after buying an additional 3,800 shares during the period. Mondrian Investment Partners LTD increased its stake in Meridian Bioscience by 13.2% in the second quarter. Mondrian Investment Partners LTD now owns 149,891 shares of the company’s stock worth $2,923,000 after buying an additional 17,502 shares during the period. Brown Capital Management LLC increased its stake in Meridian Bioscience by 0.3% in the second quarter. Brown Capital Management LLC now owns 5,724,776 shares of the company’s stock worth $111,633,000 after buying an additional 14,900 shares during the period. Finally, Nomura Holdings Inc. purchased a new stake in Meridian Bioscience during the second quarter worth approximately $226,000. 86.99% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have issued reports on VIVO. Zacks Investment Research lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Wednesday, September 28th. Canaccord Genuity reaffirmed a “hold” rating and set a $20.00 price objective on shares of Meridian Bioscience in a report on Monday, August 1st. Finally, Hilliard Lyons lowered shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Friday, July 29th. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $20.00.

About Meridian Bioscience

Meridian Bioscience, Inc (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

5 Day Chart for NASDAQ:VIVO

Receive News & Stock Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related stocks with our FREE daily email newsletter.